Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Nexium HP

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
1 1
1 1

Amoxicillin Testmiljö

Amoxicillin

Klass : 1

Visa all info

Skriv ut

Kontakta oss

  1. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of ampicillin treatment during pregnancy. Am J Obstet Gynecol 2001;185:140-7.

  2. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.

  3. United Kingdom Teratology Information Services (UKTIS). Penicillin antibiotics in pregnancy. 2017. Tillgänglig från: www.toxbase.com. Hämtad 2018-04-27.

  4. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.

  5. Daniel S, Doron M, Fishman B, Koren G, Lunenfeld E, Levy A. The safety of amoxicillin and clavulanic acid use during the first trimester of pregnancy. Br J Clin Pharmacol. 2019;85(12):2856-2863.

  1. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of ampicillin treatment during pregnancy. Am J Obstet Gynecol 2001;185:140-7.
  2. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.
  3. United Kingdom Teratology Information Services (UKTIS). Penicillin antibiotics in pregnancy. 2017. Tillgänglig från: www.toxbase.com. Hämtad 2018-04-27.
  4. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.
  5. Daniel S, Doron M, Fishman B, Koren G, Lunenfeld E, Levy A. The safety of amoxicillin and clavulanic acid use during the first trimester of pregnancy. Br J Clin Pharmacol. 2019;85(12):2856-2863.
1 1
1 1

Esomeprazol Testmiljö

Esomeprazol

Klass : 1

Visa all info

Skriv ut

Kontakta oss

  1. Matok I, Levy A, Wiznitzer A, Uziel E, Koren G, Gorodischer R. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci. 2012;57(3):699-705.

  2. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363:2114-23.

  3. Diav-Citrin O, Arnon J, Shechtman S, Shaefer C, van Tonningen MR, Clementi M et al. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 2005;21:269-75.

  4. Choi A, Noh Y, Jeong HE, Choi EY, Man KKC, Han JY et al. Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations. JAMA Netw Open. 2023;6(1):e2250366.

  5. Källén BA. Use of omeprazole during pregnancy no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 2001;96:63-8.

  6. Ruigomez A, Garcia Rodriguez LA , Cattaruzzi C, Troncon MG, Agostinis L, Wallander MA et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999;150:476-81.

  7. Kallen B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 1998;105:877-81.

  8. Lalkin A, Loebstein R, Addis A, Ramezani-Namin F, Mastroiacovo P, Mazzone T et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 1998;179:727-30.

  9. Erichsen R, Mikkelsen E, Pedersen L, Sørensen HT. Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring. Am J Ther. 2014;21(4):254-9.

  10. Choi A, Noh Y, Yon DK, Shin JY. Maternal Proton Pump Inhibitor Use During Pregnancy and Risk of Low Birth Weight in Offspring in Korea, 2008-2019. JAMA Netw Open. 2023;6(4):e237962.

  11. Lai T, Wu M, Liu J, Luo M, He L, Wang X et al. Acid-Suppressive Drug Use During Pregnancy and the Risk of Childhood Asthma: A Meta-analysis. Pediatrics. 2018;141(2):e20170889

  12. Noh Y, Jeong HE, Choi A, Choi EY, Pasternak B, Nordeng H et al. Prenatal and Infant Exposure to Acid-Suppressive Medications and Risk of Allergic Diseases in Children. JAMA Pediatr. 2023;177(3):267-277.

  1. Matok I, Levy A, Wiznitzer A, Uziel E, Koren G, Gorodischer R. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci. 2012;57(3):699-705.
  2. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363:2114-23.
  3. Diav-Citrin O, Arnon J, Shechtman S, Shaefer C, van Tonningen MR, Clementi M et al. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 2005;21:269-75.
  4. Choi A, Noh Y, Jeong HE, Choi EY, Man KKC, Han JY et al. Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations. JAMA Netw Open. 2023;6(1):e2250366.
  5. Källén BA. Use of omeprazole during pregnancy no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 2001;96:63-8.
  6. Ruigomez A, Garcia Rodriguez LA , Cattaruzzi C, Troncon MG, Agostinis L, Wallander MA et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999;150:476-81.
  7. Kallen B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 1998;105:877-81.
  8. Lalkin A, Loebstein R, Addis A, Ramezani-Namin F, Mastroiacovo P, Mazzone T et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 1998;179:727-30.
  9. Erichsen R, Mikkelsen E, Pedersen L, Sørensen HT. Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring. Am J Ther. 2014;21(4):254-9.
  10. Choi A, Noh Y, Yon DK, Shin JY. Maternal Proton Pump Inhibitor Use During Pregnancy and Risk of Low Birth Weight in Offspring in Korea, 2008-2019. JAMA Netw Open. 2023;6(4):e237962.
  11. Lai T, Wu M, Liu J, Luo M, He L, Wang X et al. Acid-Suppressive Drug Use During Pregnancy and the Risk of Childhood Asthma: A Meta-analysis. Pediatrics. 2018;141(2):e20170889
  12. Noh Y, Jeong HE, Choi A, Choi EY, Pasternak B, Nordeng H et al. Prenatal and Infant Exposure to Acid-Suppressive Medications and Risk of Allergic Diseases in Children. JAMA Pediatr. 2023;177(3):267-277.
2 2
2 2

Klaritromycin Testmiljö

Klaritromycin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021;372(0):n107.

  2. Andersen JT, Petersen M, Jimenez-Solem E, Broedbaek K, Andersen NL, Torp-Pedersen C et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. PLoS One. 2013;8:e53327.

  3. Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study. Drug Saf. 2012;35:589-98.

  4. Einarson A, Phillips E, Mawji F, D'Alimonte D, Schick B, Addis A et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998;15:523-5.

  5. Källén B, Danielsson BR. Fetal safety of erythromycin An update of Swedish data. Eur J Clin Pharmacol. 2014;70:355-60.

  6. Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368(0):m331.

  7. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.

  8. Keskin-Arslan E, Erol H, Uysal N, Karadas B, Temiz T, Kaplan YC. Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis. Reprod Toxicol. 2023;115:124-146.

  9. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24:1241-8.

  10. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053-62.

  11. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999;13:531-6.

  12. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ. 2017;189(17):E625-E633.

  1. Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021;372(0):n107.
  2. Andersen JT, Petersen M, Jimenez-Solem E, Broedbaek K, Andersen NL, Torp-Pedersen C et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. PLoS One. 2013;8:e53327.
  3. Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study. Drug Saf. 2012;35:589-98.
  4. Einarson A, Phillips E, Mawji F, D'Alimonte D, Schick B, Addis A et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998;15:523-5.
  5. Källén B, Danielsson BR. Fetal safety of erythromycin An update of Swedish data. Eur J Clin Pharmacol. 2014;70:355-60.
  6. Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368(0):m331.
  7. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.
  8. Keskin-Arslan E, Erol H, Uysal N, Karadas B, Temiz T, Kaplan YC. Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis. Reprod Toxicol. 2023;115:124-146.
  9. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24:1241-8.
  10. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053-62.
  11. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999;13:531-6.
  12. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ. 2017;189(17):E625-E633.